Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of tazemetostat and how well it
works when given together with pembrolizumab in treating patients with urothelial carcinoma
that has spread to nearby tissue or lymph nodes or other places in the body (locally
advanced/metastatic). Tazemetostat may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving tazemetostat and pembrolizumab may work
better in treating patients with urothelial carcinoma compared to pembrolizumab without
tazemetostat.